EndometriosisNCT07733583
Pelvic Floor Physical Therapy and Exercise for Women With Endometriosis and Chronic Pelvic Pain
A study testing Pelvic Floor Physical Therapy and Physical Exercise in people with Endometriosis and Chronic Pelvic Pain, run by Hospital de Clinicas de Porto Alegre at 1 site in Brazil.
Trial summary
Endometriosis is a chronic gynecological condition that can cause persistent pelvic pain, painful menstruation, painful sexual intercourse, and reduced quality of life. This study will evaluate whether specialized pelvic floor physical therapy combined with a structured physical exercise program is more effective than… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Endometriosis, Chronic Pelvic Pain
- What is being tested?
- Pelvic Floor Physical Therapy and Physical Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteBrazil
- Study dates
- 5 Mar 2026to 30 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female, aged 18 to 45 years.
- Diagnosis of endometriosis confirmed by surgery and/or imaging examinations.
- Chronic pelvic pain for at least 6 months.
- Visual Analog Scale (VAS) score ≥4 for chronic pelvic pain.
- Willingness and ability to provide written informed consent and comply with all study procedures.
Who cannot join
- Current pregnancy or planned pregnancy during the study period.
- Pelvic surgery within the previous 3 months.
- Neuromodulation treatment within the previous 3 months.
- Medical or musculoskeletal conditions that contraindicate participation in pelvic floor physical therapy or the exercise program.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site, 1 recruiting
- Recruiting
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul
Priscila Peixoto da Fonseca, PT, MSc Candidate, +5551984629624, ppfonseca@hcpa.edu.br
About this study
Official title: Pelvic Floor Physical Therapy and Physical Exercise Versus Placebo for the Treatment of Endometriosis With Chronic Pelvic Pain: A Randomized Controlled Trial
Endometriosis is a chronic gynecological condition that can cause persistent pelvic pain, painful menstruation, painful sexual intercourse, and reduced quality of life. This study will evaluate whether specialized pelvic floor physical therapy combined with a structured physical exercise program is more effective than a placebo intervention combined with the same exercise program in reducing chronic pelvic pain in women with endometriosis. Participants will be randomly assigned to one of the two groups and followed for 12 weeks.
Read the detailed description
Endometriosis is a chronic estrogen-dependent inflammatory disease frequently associated with chronic pelvic pain, dysmenorrhea, dyspareunia, impaired quality of life, sexual dysfunction, and central pain sensitization. Although pelvic floor physical therapy and exercise have demonstrated potential benefits, high-quality randomized placebo-controlled trials evaluating their combined effects remain limited.
This study is a prospective, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the effectiveness of specialized pelvic floor physical therapy combined with a structured physical exercise program compared with a placebo intervention combined with the same exercise program in women with confirmed endometriosis and chronic pelvic pain.
Sixty-four participants will be randomly allocated (1:1) to either the intervention group or the placebo group. Both groups will participate in the same 12-week progressive exercise program. The intervention group will receive specialized pelvic floor physical therapy, whereas the control group will receive a placebo pelvic floor physical therapy protocol designed to maintain participant blinding without providing specific therapeutic effects.
Participants will be evaluated at baseline (week 0), after 8 weeks, and at the end of the 12-week intervention. The primary outcome is the intensity of chronic pelvic pain. Secondary outcomes include neuropathic pain symptoms, central sensitization, quality of life, sexual function, depressive symptoms, pelvic floor muscle function, treatment adherence, and participant satisfaction.
- Conditions
- Endometriosis, Chronic Pelvic Pain
- Being tested
- Pelvic Floor Physical Therapy, Placebo Pelvic Floor Physical Therapy, Physical Exercise
- Keywords
- Pelvic Floor Physical Therapy, Chronic Pelvic Pain, Endometriosis, Randomized Controlled Trial, Physical Exercise, Quality of Life, Dyspareunia, Dysmenorrhea
- Medical subject headings
- Endometriosis, Motor Activity, Dyspareunia, Dysmenorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pelvic Floor Physical TherapyBehavioural
Specialized pelvic floor physical therapy administered over 12 weeks, including individualized assessment and evidence-based treatment targeting pelvic floor dysfunction associated with endometriosis-related chronic pelvic pain. Treatment may include manual therapy, pelvic floor muscle training, therapeutic exercises, education, and other physiotherapy techniques according to participants' clinical findings.
Placebo Pelvic Floor Physical TherapyBehavioural
Placebo pelvic floor physical therapy administered over 12 weeks using procedures designed to maintain participant blinding without providing specific therapeutic effects. Participants will receive the same number and duration of sessions as the experimental group.
Physical ExerciseBehavioural
A structured progressive physical exercise program administered over 12 weeks, consisting of six progressive phases and provided equally to participants in both study arms.
| Study group | Role | What they receive |
|---|---|---|
| Pelvic Floor Physical Therapy Plus Physical Exercise | Experimental | Participants assigned to this arm will receive specialized pelvic floor physical therapy combined with a structured progressive physical exercise program for 12 weeks. Receives: Behavioral: Pelvic Floor Physical Therapy; Behavioral: Physical Exercise |
| Placebo Pelvic Floor Physical Therapy Plus Physical Exercise | Placebo comparator | Participants assigned to this arm will receive a placebo pelvic floor physical therapy intervention combined with the same structured progressive physical exercise program for 12 weeks. Receives: Behavioral: Placebo Pelvic Floor Physical Therapy; Behavioral: Physical Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Chronic Pelvic Pain Intensity
The primary outcome is the change in pain intensity measured using the Visual Analog Scale (VAS), a 0 to 10 scale in which 0 indicates no pain and 10 indicates the worst pain imaginable, for chronic pelvic pain, dysmenorrhea, and dyspareunia, from baseline to Week 8 and Week 12.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Secondary outcomes (20)
Neuropathic Pain Symptoms (painDETECT)
Neuropathic pain symptoms will be assessed using the painDETECT questionnaire. The outcome is the change in the total painDETECT score from baseline to after 8 treatment sessions and after completion of the 12-session intervention.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Central Sensitization Symptoms (CSI-A)
Central sensitization symptoms will be assessed using the Central Sensitization Inventory (CSI-A). The outcome is the change in the total CSI-A score from baseline to after 8 treatment sessions and after completion of the 12-session intervention.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Female Sexual Function (FSFI)
Female sexual function will be assessed using the Female Sexual Function Index (FSFI). The outcome is the change in the total FSFI score from Baseline to after 8 treatment sessions and after completion of the 12-session intervention. Scores range from 2 to 36 points, with higher scores indicating better female sexual function.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Endometriosis-Specific Quality of Life (EHP-30)
Health-related quality of life will be assessed using the Endometriosis Health Profile-30 (EHP-30). The EHP-30 is a 30-item questionnaire assessing five core domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Scores for each domain are transformed to a standardized 0-100 scale, with higher scores indicating worse health-related quality of life.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
General Quality of Life (WHOQOL-BREF)
Health-related quality of life will be assessed using the World Health Organization Quality of Life Instrument, Brief Version (WHOQOL-BREF), a 26-item questionnaire that assesses four domains: physical health, psychological health, social relationships, and environment. The outcome is the change in domain scores from baseline to after 8 treatment sessions and after completion of the 12-session intervention.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Depressive Symptoms (BDI)
Depressive symptoms will be assessed using the Beck Depression Inventory (BDI). The outcome is the change in the total BDI score from baseline to after 8 treatment sessions and after completion of the 12-session intervention.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Treatment Adherence
Treatment adherence will be assessed throughout the intervention by recording attendance at supervised treatment sessions and adherence to the prescribed home exercise program using participant adherence records.
Measured: Throughout the 12-session intervention (approximately 12 weeks).
Participant Satisfaction
Participant satisfaction will be assessed after completion of the 12-session intervention using a study-specific questionnaire composed of 13 items rated on a 5-point Likert scale (1 = Strongly disagree to 5 = Strongly agree). Individual item responses will be analyzed to evaluate participants' perceptions of the intervention.
Measured: After completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Strength (Modified Oxford Scale)
Pelvic floor muscle strength will be assessed using the Modified Oxford Scale during standardized digital vaginal examination. The outcome is the change in muscle strength score from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Scores range from 0 to 5, with higher scores indicating greater pelvic floor muscle strength.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Endurance
Pelvic floor muscle endurance will be assessed as the maximum duration of a sustained voluntary pelvic floor muscle contraction during standardized digital vaginal examination. The outcome is the change in contraction duration from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Endurance is recorded in seconds, with higher values indicating greater muscle endurance.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Repetitions of Sustained Contractions
Pelvic floor muscle repetitions will be assessed as the number of sustained voluntary contractions performed before fatigue during standardized digital vaginal examination. The outcome is the change in the number of repetitions from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Higher values indicate greater muscular endurance.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Fast Contractions
Fast pelvic floor muscle contractions will be assessed as the maximum number of rapid voluntary contractions completed in sequence during standardized digital vaginal examination. The outcome is the change in the number of fast contractions from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Higher values indicate better pelvic floor muscle performance.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Resting Pelvic Floor Muscle Tone
Resting pelvic floor muscle tone will be assessed during standardized digital vaginal examination. The outcome is the change in resting muscle tone classification from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Muscle tone is classified as hypotonic, normal, or hypertonic.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Relaxation
Pelvic floor muscle relaxation will be assessed during standardized digital vaginal examination following maximal voluntary contraction. The outcome is the change in relaxation ability from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Relaxation is classified as complete, partial, or absent.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain on Palpation
Pain on pelvic floor muscle palpation will be assessed during standardized digital vaginal examination. The outcome is the change in the presence or absence of pain on palpation from baseline to after 8 treatment sessions and after completion of the 12-session intervention.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain Intensity on Palpation (Visual Analog Scale - VAS)
Pain intensity during pelvic floor muscle palpation will be assessed using the Visual Analog Scale (VAS). The outcome is the change in pain intensity score from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain Location on Palpation
Pain location during standardized digital vaginal examination will be assessed by documenting the anatomical location(s) in which pain is reported during pelvic floor muscle palpation. The outcome is the change in pain location from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Pain location is recorded as superficial, deep, rectal, or other.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Elevation
Pelvic floor muscle elevation during voluntary contraction will be assessed during standardized digital vaginal examination. The outcome is the change in the presence of cranial elevation of the pelvic floor muscles from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Elevation is classified as present or absent.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Co-contraction
Co-contraction will be assessed during standardized digital vaginal examination by recording activation of synergistic muscles during voluntary pelvic floor muscle contraction. The outcome is the change in co-contraction pattern from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Co-contraction is classified as none, transversus abdominis, gluteal muscles, adductor muscles, multiple muscles, or other.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Timing
Timing of pelvic floor muscle contraction will be assessed by evaluating the ability to voluntarily contract the pelvic floor muscles before or simultaneously with increased intra-abdominal pressure during standardized digital vaginal examination. The outcome is the change in timing classification from baseline to after 8 treatment sessions and after completion of the 12-session intervention. Timing is classified as present or absent.
Measured: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study start5 Mar 2026
- Primary completion14 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Hospital de Clinicas de Porto AlegreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned in a 1:1 ratio to either the intervention group or the placebo control group.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital de Clinicas de Porto Alegre
- Sponsor type
- University, hospital or other
- Collaborators
- Federal University of Rio Grande do Sul
- Responsible party
- Sponsor
- Investigators
- João da Cunha Filho, PhD, Study director, Hospital de Clinicas de Porto Alegre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07733583
- Sponsor's protocol ID
- 2025-0492
- Status last verified
- Jul 2026
- First submitted
- 20 Jul 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pelvic Floor Physical Therapy and Physical Exercise Versus Placebo for the Treatment of Endometriosis With Chronic Pelvic Pain: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07733583
- Acronym / sponsor ID
- 2025-0492
- Conditions
- Endometriosis, Chronic Pelvic Pain
- Keywords
- Pelvic Floor Physical Therapy, Chronic Pelvic Pain, Endometriosis, Randomized Controlled Trial, Physical Exercise, Quality of Life, Dyspareunia, Dysmenorrhea
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 64 participants (estimated)
- Lead sponsor
- Hospital de Clinicas de Porto AlegreUniversity, hospital or other
- Collaborators
- Federal University of Rio Grande do Sul
- Study start
- 5 Mar 2026 (actual)
- Primary completion
- 14 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endometriosis is a chronic gynecological condition that can cause persistent pelvic pain, painful menstruation, painful sexual intercourse, and reduced quality of life. This study will evaluate whether specialized pelvic floor physical therapy combined with a structured physical exercise program is more effective than a placebo intervention combined with the same exercise program in reducing chronic pelvic pain in women with endometriosis. Participants will be randomly assigned to one of the two groups and followed for 12 weeks.
Detailed description
Endometriosis is a chronic estrogen-dependent inflammatory disease frequently associated with chronic pelvic pain, dysmenorrhea, dyspareunia, impaired quality of life, sexual dysfunction, and central pain sensitization. Although pelvic floor physical therapy and exercise have demonstrated potential benefits, high-quality randomized placebo-controlled trials evaluating their combined effects remain limited.
This study is a prospective, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the effectiveness of specialized pelvic floor physical therapy combined with a structured physical exercise program compared with a placebo intervention combined with the same exercise program in women with confirmed endometriosis and chronic pelvic pain.
Sixty-four participants will be randomly allocated (1:1) to either the intervention group or the placebo group. Both groups will participate in the same 12-week progressive exercise program. The intervention group will receive specialized pelvic floor physical therapy, whereas the control group will receive a placebo pelvic floor physical therapy protocol designed to maintain participant blinding without providing specific therapeutic effects.
Participants will be evaluated at baseline (week 0), after 8 weeks, and at the end of the 12-week intervention. The primary outcome is the intensity of chronic pelvic pain. Secondary outcomes include neuropathic pain symptoms, central sensitization, quality of life, sexual function, depressive symptoms, pelvic floor muscle function, treatment adherence, and participant satisfaction.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned in a 1:1 ratio to either the intervention group or the placebo control group.
| Arm | Type | Receives |
|---|---|---|
| Pelvic Floor Physical Therapy Plus Physical Exercise | Experimental | Behavioral: Pelvic Floor Physical Therapy, Behavioral: Physical ExerciseParticipants assigned to this arm will receive specialized pelvic floor physical therapy combined with a structured progressive physical exercise program for 12 weeks. |
| Placebo Pelvic Floor Physical Therapy Plus Physical Exercise | Placebo comparator | Behavioral: Placebo Pelvic Floor Physical Therapy, Behavioral: Physical ExerciseParticipants assigned to this arm will receive a placebo pelvic floor physical therapy intervention combined with the same structured progressive physical exercise program for 12 weeks. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Female, aged 18 to 45 years.
- Diagnosis of endometriosis confirmed by surgery and/or imaging examinations.
- Chronic pelvic pain for at least 6 months.
- Visual Analog Scale (VAS) score ≥4 for chronic pelvic pain.
- Willingness and ability to provide written informed consent and comply with all study procedures.
Key exclusion criteria (4 listed)
- Current pregnancy or planned pregnancy during the study period.
- Pelvic surgery within the previous 3 months.
- Neuromodulation treatment within the previous 3 months.
- Medical or musculoskeletal conditions that contraindicate participation in pelvic floor physical therapy or the exercise program.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pelvic Floor Physical TherapySpecialized pelvic floor physical therapy administered over 12 weeks, including individualized assessment and evidence-based treatment targeting pelvic floor dysfunction associated with endometriosis-related chronic pelvic pain. Treatment may include manual therapy, pelvic floor muscle training, therapeutic exercises, education, and other physiotherapy techniques according to participants' clinical findings. | Behavioural | Pelvic Floor Physical Therapy Plus Physical Exercise |
| Placebo Pelvic Floor Physical TherapyPlacebo pelvic floor physical therapy administered over 12 weeks using procedures designed to maintain participant blinding without providing specific therapeutic effects. Participants will receive the same number and duration of sessions as the experimental group. | Behavioural | Placebo Pelvic Floor Physical Therapy Plus Physical Exercise |
| Physical ExerciseA structured progressive physical exercise program administered over 12 weeks, consisting of six progressive phases and provided equally to participants in both study arms. | Behavioural | Pelvic Floor Physical Therapy Plus Physical Exercise, Placebo Pelvic Floor Physical Therapy Plus Physical Exercise |
Primary outcome
Chronic Pelvic Pain Intensity
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
The primary outcome is the change in pain intensity measured using the Visual Analog Scale (VAS), a 0 to 10 scale in which 0 indicates no pain and 10 indicates the worst pain imaginable, for chronic pelvic pain, dysmenorrhea, and dyspareunia, from baseline to Week 8 and Week 12.
20 secondary outcomes
Neuropathic Pain Symptoms (painDETECT)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Central Sensitization Symptoms (CSI-A)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Female Sexual Function (FSFI)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Endometriosis-Specific Quality of Life (EHP-30)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
General Quality of Life (WHOQOL-BREF)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Depressive Symptoms (BDI)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Treatment Adherence
Time frame: Throughout the 12-session intervention (approximately 12 weeks).
Participant Satisfaction
Time frame: After completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Strength (Modified Oxford Scale)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Endurance
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Repetitions of Sustained Contractions
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Fast Contractions
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Resting Pelvic Floor Muscle Tone
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Relaxation
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain on Palpation
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain Intensity on Palpation (Visual Analog Scale - VAS)
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pain Location on Palpation
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Pelvic Floor Muscle Elevation
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Co-contraction
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Timing
Time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
João da Cunha Filho, PhD study director
Hospital de Clinicas de Porto Alegre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pelvic Floor Physical Therapy and Physical Exercise in people with Endometriosis and Chronic Pelvic Pain, run by Hospital de Clinicas de Porto Alegre at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Priscila Peixoto da Fonseca, PT, MSc Candidate (+5551984629624, ppfonseca@hcpa.edu.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Chronic Pelvic Pain Intensity (time frame: Baseline; after 8 treatment sessions (approximately 8 weeks); after completion of the 12-session intervention (approximately 12 weeks).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.